Business context and reporting period
This is Obalon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020—not a filing for Vyome Holdings, Inc. Obalon developed and commercialized the FDA-approved Obalon Balloon System for weight loss. In 2020, it halted commercial operations and manufacturing, closed its branded treatment centers, and shifted its focus to seeking third-party reimbursement and evaluating strategic alternatives.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $44,000 | $333,000 | $1.527 million | $2.494 million |
| Gross profit (loss) | $3,000 | $(79,000) | $522,000 | $171,000 |
| Operating expenses | $1.562 million | $3.663 million | $11.149 million | $18.426 million |
| Net loss | $(1.560) million | $(3.706) million | $(11.009) million | $(18.763) million |
| Net loss per share | $(0.20) | $(0.61) | $(1.42) | $(5.07) |
- Q3 gross margin was approximately 7%; nine-month gross margin was approximately 34%, compared with approximately 7% in the prior-year period. The nine-month improvement included reversals of revenue-related reserves after commercial programs ended.
- At September 30, cash and cash equivalents were $5.514 million, down from $14.055 million at December 31, 2019. Current assets were $9.031 million and current liabilities were $5.050 million. Total liabilities were $6.040 million and stockholders’ equity was $5.922 million.
- Operating cash use was $8.854 million for the first nine months, versus $17.987 million in 2019. Investing activities used $117,000; financing provided $430,000, from the Paycheck Protection Program (PPP) loan. Cash declined by $8.541 million.
- The $430,000 unsecured PPP loan bears 1% interest and matures April 2022; forgiveness had not been requested as of September 30. The filing reports no long-term debt at year-end 2019.
Material changes and unusual items
- Revenue fell 87% in Q3 and 39% for the first nine months year over year, principally reflecting suspended operations and abandonment of the retail-center model. Q3 revenue related to treatments already underway before the suspension; nine-month revenue also included reserve reversals. The company said it did not expect meaningful revenue for the foreseeable future.
- Operating expenses declined substantially as operations and staffing were reduced; by August, the company had two full-time employees. Nine-month results included $1.310 million in asset impairment and other charges, primarily related to retail-center assets and inventory after the strategy shift.
- Other current assets included a $3.150 million insurance receivable corresponding to a $3.150 million accrual for settlement of a securities class action. The company expected insurance to cover the settlement, which remained subject to final court approval. It also recorded a $600,000 directors’ and officers’ insurance refund as a reduction of Q3 SG&A expense.
- The company had not paid rent on its headquarters and Orange County center since April. In October 2020, its Carlsbad landlord brought an unlawful detainer action alleging more than $113,000 in unpaid rent and fees; the company disputed the claims.
Outlook, risks and contingencies
Management stated that existing cash was expected to fund operations through the end of 2020, but the filing concludes there was substantial doubt about the company’s ability to continue as a going concern for the twelve months following issuance. Continued operations depended on raising capital or completing a strategic alternative; management warned that failure could lead to asset sales, liquidation, or bankruptcy protection.
- The company was pursuing reimbursement and coverage for the Obalon system while exploring strategic alternatives, with Canaccord Genuity engaged as financial advisor. Reimbursement was uncertain and could take years; management said additional capital might be needed if these efforts advanced.
- COVID-19, the suspension of elective procedures, shutdown of treatment centers, terminated international distribution, and paused manufacturing materially impaired operations. The company had no plan to reopen centers or resume shipments.
- Nasdaq had notified the company of deficiencies in minimum stockholders’ equity and minimum bid price. As of the filing, Nasdaq had not granted the requested extension for the equity deficiency; the company faced possible delisting if it failed to regain compliance.
- The filing reported that disclosure controls and procedures were effective at a reasonable-assurance level and no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Check subsequent filings for cash runway, financing, strategic transactions, and any going-concern developments.
- Verify the status and outcome of the Nasdaq listing deficiencies and any delisting or market transfer.
- Confirm court approval and insurance payment for the $3.150 million securities settlement, and the outcome of the landlord dispute.
- Check whether the PPP loan was forgiven or repaid and whether reimbursement efforts produced coverage, clinical-study progress, or new funding.